The FDA did not rule out reconsidering omaveloxolone’s application once the new study has been completed, Reata noted.
Saturday, December 26, 2020
FDA requests new trial for Reata's Friedreich's ataxia program; J&J's Tremfya picks up expanded label in Europe
Endpoints News, November 25, 2020. Three months after Reata Pharmaceuticals suggested its Friedreich’s ataxia program omaveloxolone could be delayed, the company revealed that is indeed going to be the case.
Subscribe to:
Posts (Atom)
